PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes

Cell Death and Differentiation

Volumn 11, Issue 10, 2004, Pages 1084-1091

  Larribere, L ^a   Khaled, M ^a   Tartare Deckert, S ^a   Busca, R ^a   Luciano, F ^a   Bille, K ^a   Valony, G ^a   Eychene, A ^b   Auberger, P ^a   Ortonne, J P ^a   Ballotti, R ^a   Bertolotto, C ^a  

^a INSERM   (France)

^b INSTITUT CURIE   (France)

Author keywords

Apoptosis; ERK; Melanocyte; PI3K; SCF; TRAIL

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; FLICE INHIBITORY PROTEIN; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAUROSPORINE; STEM CELL FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROTECTION; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TARGETING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELLS, CULTURED; ENZYME ACTIVATION; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; HUMANS; KERATINOCYTES; MELANOCYTES; MELANOMA; MEMBRANE GLYCOPROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STEM CELL FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 5044240701     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401475     Document Type: Article

References (54)

1. Ashkenazi A and Dixit VM (1998) Death receptors: signaling, modulation. Science 281: 1305-1308
2. LeBlanc HN and Ashkenazi A (2003) Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10: 66-75
3. Hasegawa J, Kamada S, Kamiike W, Shimizu S, Imazu T, Matsuda H and Tsujimoto Y (1996) Involvement of CPP32/Yama(-like) proteases in Fas-mediated apoptosis. Cancer Res. 56: 1713-1718
4. Peter ME and Krammer PH (1998) Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr. Opin. Immunol. 10: 545-551
5. Kroemer G (1997) The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat. Med. 3: 614-620
6. Kroemer G, Zamzami N and Susin SA (1997) Mitochondrial control of apoptosis. Immunol. Today 18: 44-51
7. Veis DJ, Sorenson CM, Shutter JR and Korsmeyer SJ (1993) Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75: 229-240
8. Zhai S, Yaar M, Doyle SM and Gilchrest BA (1996) Nerve growth factor rescues pigment cells from ultraviolet-induced apoptosis by upregulating BCL-2 levels. Exp. Cell Res. 224: 335-343
9. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK, Lin YL, Ramaswamy S, Avery W, Ding HF, Jordan SA, Jackson IJ, Korsmeyer SJ, Golub TR and Fisher DE (2002) Bcl2 regulation by the melanocyte master regulator mitf modulates lineage survival and melanoma cell viability. Cell 109: 707-718
10. Hussein MR, Haemel AK and Wood GS (2003) Apoptosis and melanoma: molecular mechanisms. J. Pathol. 199: 275-288
11. Griffith TS, Chin WA, Jackson GC, Lynch DH and Kubin MZ (1998) Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161: 2833-2840
12. Zhang XD, Nguyen T, Thomas WD, Sanders JE and Hersey P (2000) Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett. 482: 193-199
13. Spritz RA (1994) Molecular basis of human piebaldism. J. Invest. Dermatol. 103: 137S-140S
14. Ito M, Kawa Y, Ono H, Okura M, Baba T, Kubota Y, Nishikawa SI and Mizoguchi M (1999) Removal of stem cell factor or addition of monoclonal anti-c-KIT antibody induces apoptosis in murine melanocyte precursors. J. Invest. Dermatol. 112: 796-801
15. Kunisada T, Lu SZ, Yoshida H, Nishikawa S, Mizoguchi M, Hayashi S, Tyrrell L, Williams DA, Wang X and Longley BJ (1998a) Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor. J. Exp. Med. 187: 1565-1573
16. Noonan FP, Recio JA, Takayama H, Duray P, Anver MR, Rush WL, De Fabo EC and Merlino G (2001) Neonatal sunburn and melanoma in mice. Nature 413: 271-272
17. Neri LM, Borgatti P, Capitani S and Martelli AM (2002) The nuclear phosphoinositide 3-kinase/AKT pathway: a new second messenger system. Biochim. Biophys. Acta 1584: 73-80
18. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA (2003a) Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17: 590-603
19. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA and McCubrey JA (2003b) Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17: 1263-1293
20. Reddy KB, Nabha SM and Atanaskova N (2003) Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev. 22: 395-403
21. Srivastava RK (2001) TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3: 535-546
22. Gescher A (1998) Analogs of staurosporine: potential anticancer drugs? Gen. Pharmacol. 31: 721-728
23. Stepczynska A, Lauber K, Engels IH, Janssen O, Kabelitz D, Wesselborg S and Schulze-Osthoff K (2001) Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation. Oncogene 20: 1193-1202
24. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR and Strom SC (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6: 564-567
25. Thomas WD and Hersey P (1998) TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4T cell killing of target cells. J. Immunol. 161: 2195-2200
26. Thomas WD, Zhang XD, Franco AV, Nguyen T and Hersey P (2000) TNF-related apoptosis-inducing ligand-induced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of mitochondria. J. Immunol. 165: 5612-5620
27. Zhang XD, Borrow JM, Zhang XY, Nguyen T and Hersey P (2003) Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 22: 2869-2881
28. Zhang XD, Zhang XY, Gray CP, Nguyen T and Hersey P (2001) Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res. 61: 7339-7348
29. Werner AB, de Vries E, Tait SW, Bontjer I and Borst J (2002) TRAIL receptor and CD95 signal to mitochondria via FADD, caspase-8/10, Bid, and Bax but differentially regulate events downstream from truncated Bid. J. Biol. Chem. 277: 40760-40767
30. Helmbach H, Rossmann E, Kern MA and Schadendorf D (2001) Drug-resistance in human melanoma. Int. J. Cancer 93: 617-622
31. Kos L, Aronzon A, Takayama H, Maina F, Ponzetto C, Merlino G and Pavan W (1999) Hepatocyte growth factor/scatter factor-MET signaling in neural crest-derived melanocyte development. Pigment Cell Res. 12: 13-21
32. Otsuka T, Takayama H, Sharp R, Celli O, LaRochelle WJ, Bottaro DP, Ellmore N, Vieira W, Owens JW, Anver M and Merlino G (1998) c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res. 58: 5157-5167
33. Hamoen KE, Borel Rinkes IH and Morgan JR (2001) Hepatocyte growth factor and melanoma: gene transfer studies in human melanocytes. Melanoma Res. 11: 89-97
34. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K and Herlyn M (2001) Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 20: 8125-8135
35. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR and Weber BL (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62: 6997-7000
36. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954
37. Calipel A, Lefevre G, Pouponnot C, Mouriaux F, Eychene A and Mascarelli F (2003) Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J. Biol. Chem. 278: 42409-42418
38. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M and Tuveson DA (2003) Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 63: 5198-5202
39. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM and Meltzer PS (2003) High frequency of BRAF mutations in nevi. Nat. Genet. 33: 19-20
40. Uribe P, Wistuba II and Gonzalez S (2003) BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am. J. Dermatopathol. 25: 365-370
41. Krasilnikov M, Ivanov VN, Dong J and Ronai Z (2003) ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 22: 4092-4101
42. Murakami T, Cardones AR, Finkelstein SE, Restifo NP, Klaunberg BA, Nestle FO, Castillo SS, Dennis PA and Hwang ST (2003) Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J. Exp. Med. 198: 1337-1347
43. Stewart AL, Mhashilkar AM, Yang XH, Ekmekcioglu S, Saito Y, Sieger K, Schrock R, Onishi E, Swanson X, Mumm JB, Zumstein L, Watson GJ, Snary D, Roth JA, Grimm EA, Ramesh R and Chada S (2002) PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol. Med. 8: 451-461
44. Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ and Eng C (2000) Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am. J. Pathol. 157: 1123-1128
45. Miyashita T, Kawakami A, Tamai M, Izumi Y, Mingguo H, Tanaka F, Abiru S, Nakashima K, Iwanaga N, Aratake K, Kamachi M, Arima K, Ida H, Migita K, Origuchi T, Tagashira S, Nishikaku F and Eguchi K (2003) Akt is an endogenous inhibitor toward tumor necrosis factor-related apoptoss inducing ligand-mediated apoptosis in rheumatoid synovial cells. Biochem. Biophys. Res. Commun. 812: 397-404
46. Schulze-Bergkamen H, Brenner D, Krueger A, Suess D, Fas SC, Frey CR, Dax A, Zink D, Buchler P, Muller M and Krammer PH (2004) Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt. Hepatology 39: 645-654
47. Huang CL, Nordlund JJ and Boissy R (2002) Vitiligo: a manifestation of apoptosis? Am. J. Clin. Dermatol. 3: 301-308
48. Moretti S, Spallanzani A, Amato L, Hautmann G, Gallerani I, Fabiani M and Fabbri P (2002) New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res. 15: 87-92
49. Hachiya A, Kobayashi A, Ohuchi A, Takema Y and Imokawa G (2001 The paracrine role of stem cell factor/c-kit signaling in the activation of human melanocytes in ultraviolet-B-induced pigmentation. J. Invest. Dermatol. 116: 578-586
50. Autier P, Severi G, Pedeux R, Cattaruzza MS, Boniol M, Grivegnee A and Dore JF (2003) Number, size of nevi are influenced by different sun exposure components: implications for the etiology of cutaneous melanoma (Belgium, Germany, France, Italy). Cancer Causes Control 14: 453-459
51. Kunisada T, Yoshida H, Yamazaki H, Miyamoto A, Hemmi H, Nishimura E, Shultz LD, Nishikawa S and Hayashi S (1998b) Transgene expression of steel factor in the basal layer of epidermis promotes survival, proliferation, differentiation and migration of melanocyte precursors. Development 125: 2915-2923
52. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z and Schwall RH (1999) Safety, antitumor activity of recombinant soluble Apo2 ligand. J. Cell. Invest. 104: 155-162
53. Chaussade C, Pirola L, Bonnafous S, Blondeau F, Brenz-Verca S, Tronchere H, Portis F, Rusconi S, Payrastre B, Laporte J and Van Obberghen E (2003) Expression of myotubularin by an adenoviral vector demonstrates its function as a PtdIns(3)P phosphatase in muscle cell lines. Involvement of PtdIns(3)P in insulin-stimulated glucose transport. Mol. Endocrinol. 17: 2448-2460
54. Gaggioli C, Busca R, Abbe P, Ortonne JP and Ballotti R (2003) Microphthalmia-associated transcription factor (MITF) is required but is not sufficient to induce the expression of melanogenic genes. Pigment Cell Res. 16: 374-382